Pathogen reduction technology (Mirasol®) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS

Background and Objectives Mirasol (R) pathogen reduction technology (PRT) for platelet concentrates uses riboflavin and ultraviolet light. Previously, we described increased metabolism and activation for PRT platelets stored in 100% plasma. To improve platelet quality, we resuspended platelets in a mixture of plasma and platelet additive solution (PAS). Materials and Methods Single-donor platelets were resuspended in plasma and split into an untreated control and a PRT-treated single product. One hundred and fifty millilitre PAS (SSP+) was added to both. Over 7 days, we assayed pH, glucose consumption-, lactate production rate and CD62p with and without TRAP. Results On day 5, PRT units showed a significantly lower pH (7 center dot 087 +/- 0 center dot 105 vs. 7 center dot 288 +/- 0 center dot 200) accompanied by a higher lactate production (0 center dot 104 +/- 0014 vs. 0 center dot 063 +/- 0 center dot 017 mmol/1012/h) and glucose consumption rate (0 center dot 039 +/- 0005 vs. 0 center dot 028 +/- 0 center dot 009 mmol/1012 platelets/h). CD62p expression was higher in treated units (44 center dot 5 +/- 13 center dot 0 vs. 16 center dot 5 +/- 7 center dot 6%). Conclusion In comparison to PRT platelets resuspended in 100% plasma, a mixture of plasma and PAS improves pH and platelet metabolism but not platelet activation. Prolonged shelf-life for up to 7 days may be possible.